AR109079A1 - Formas cristalinas de 4-ciano-n-(2-(4,4-dimetilciclohex-1-en-1-il)-6-(2,2,6,6-tetrametiltetrahidro-2h-piran-4-il)piridin-3-il)1h-imidazol-2-carboxamida - Google Patents
Formas cristalinas de 4-ciano-n-(2-(4,4-dimetilciclohex-1-en-1-il)-6-(2,2,6,6-tetrametiltetrahidro-2h-piran-4-il)piridin-3-il)1h-imidazol-2-carboxamidaInfo
- Publication number
- AR109079A1 AR109079A1 ARP170101991A ARP170101991A AR109079A1 AR 109079 A1 AR109079 A1 AR 109079A1 AR P170101991 A ARP170101991 A AR P170101991A AR P170101991 A ARP170101991 A AR P170101991A AR 109079 A1 AR109079 A1 AR 109079A1
- Authority
- AR
- Argentina
- Prior art keywords
- degrees
- compound
- peaks
- produces
- diffraction pattern
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Tropical Medicine & Parasitology (AREA)
- Communicable Diseases (AREA)
- Orthopedic Medicine & Surgery (AREA)
- AIDS & HIV (AREA)
- Rheumatology (AREA)
- Molecular Biology (AREA)
- Physical Education & Sports Medicine (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Liquid Crystal Substances (AREA)
- Pyrane Compounds (AREA)
Abstract
Reivindicación 1: Una forma cristalina de 4-ciano-N-[2-(4,4-dimetilciclohex-1-en-1-il)-6-(2,2,6,6-tetrametiltetrahidro-2H-piran-4-il)piridin-3-il]-1H-imidazol-2-carboxamida (compuesto A) de fórmula (1), en donde la forma cristalina se selecciona del grupo que consiste en: la forma I del compuesto A, que produce un patrón de difracción de polvo de rayos X que comprende picos a 6,1, 9,2, 9,4, 12,7, 15,1, 15,7, y 18,4 grados 2q ± 0,2 grados 2q; la forma II del compuesto A, que produce un patrón de difracción de polvo de rayos X que comprende picos a 6,3, 7,3, 11,5, 17,0 y 18,3 grados 2q ± 0,2 grados 2q; la forma IIA del compuesto A, que produce un patrón de difracción de polvo de rayos X que comprende picos a 6,4, 14,1, 14,6, 17,1, 18,3, 18,9, 19,3 y 23,0 grados 2q ± 0,2 grados 2q; la forma IIB del compuesto A, que produce un patrón de difracción de polvo de rayos X que comprende picos a 6,3 y 18,9 grados 2q ± 0,2 grados 2q; la forma III del compuesto A, que produce un patrón de difracción de polvo de rayos X que comprende picos a 4,6, 6,3, 6,8, 9,1, 17,1, y 28,5 grados 2q ± 0,2 grados 2q; la forma IV del compuesto A, que produce un patrón de difracción de polvo de rayos X que comprende picos a 6,3, 6,6, 6,9, 7,3, 11,7, 17,1 y 18,3 grados 2q ± 0,2 grados 2q; la forma V del compuesto A, que produce un patrón de difracción de polvo de rayos X que comprende picos a 6,3, 7,4, 11,5, 11,7, 17,0, 18,3 y 23,0 grados 2q ± 0,2 grados 2q; y la forma VI del compuesto A, que produce un patrón de difracción de polvo de rayos X que comprende picos a 5,7, 10,8, 11,4 y 17,1 grados 2q ± 0,2 grados 2q.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662363622P | 2016-07-18 | 2016-07-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR109079A1 true AR109079A1 (es) | 2018-10-24 |
Family
ID=59631847
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP170101991A AR109079A1 (es) | 2016-07-18 | 2017-07-17 | Formas cristalinas de 4-ciano-n-(2-(4,4-dimetilciclohex-1-en-1-il)-6-(2,2,6,6-tetrametiltetrahidro-2h-piran-4-il)piridin-3-il)1h-imidazol-2-carboxamida |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US10314821B2 (es) |
| EP (1) | EP3484872B1 (es) |
| JP (1) | JP2019521159A (es) |
| KR (1) | KR20190026910A (es) |
| CN (1) | CN109952296A (es) |
| AR (1) | AR109079A1 (es) |
| AU (1) | AU2017299506B2 (es) |
| BR (1) | BR112019000982A2 (es) |
| CA (1) | CA3031230A1 (es) |
| EA (1) | EA201990320A1 (es) |
| ES (1) | ES2935647T3 (es) |
| MA (1) | MA45685A (es) |
| MX (2) | MX2019000749A (es) |
| TW (1) | TWI752980B (es) |
| UY (1) | UY37338A (es) |
| WO (1) | WO2018017444A1 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20230104185A (ko) * | 2020-10-30 | 2023-07-07 | 아테넥스 알앤디, 엘엘씨 | Hm30181 메실레이트의 다형성(polymorphisms of hm30181 mesylate) |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO3240B1 (ar) * | 2007-10-17 | 2018-03-08 | Janssen Pharmaceutica Nv | c-fms مثبطات كيناز |
| WO2009058968A2 (en) * | 2007-10-31 | 2009-05-07 | Janssen Pharmaceutica N.V. | Biomarker for assessing response to fms treatment |
| JOP20180012A1 (ar) * | 2012-08-07 | 2019-01-30 | Janssen Pharmaceutica Nv | عملية السلفنة باستخدام نونافلوروبوتانيسولفونيل فلوريد |
| HUE036925T2 (hu) * | 2013-03-15 | 2018-08-28 | Janssen Pharmaceutica Nv | C-fms kináz inhibitorként használható helyettesített piridin származékok |
| CN105283185A (zh) * | 2013-03-15 | 2016-01-27 | 詹森药业有限公司 | 用于治疗何杰金氏淋巴瘤的4-氰基-n-(2-(4，4-二甲基环己-1-烯-1-基)-6-(2，2，6，6-四甲基四氢-2h-吡喃-4-基)吡啶-3-基)-1h-咪唑-2-酰胺 |
-
2017
- 2017-07-14 TW TW106123583A patent/TWI752980B/zh active
- 2017-07-17 CA CA3031230A patent/CA3031230A1/en active Pending
- 2017-07-17 MX MX2019000749A patent/MX2019000749A/es unknown
- 2017-07-17 KR KR1020197004327A patent/KR20190026910A/ko not_active Application Discontinuation
- 2017-07-17 MA MA045685A patent/MA45685A/fr unknown
- 2017-07-17 AR ARP170101991A patent/AR109079A1/es unknown
- 2017-07-17 EA EA201990320A patent/EA201990320A1/ru unknown
- 2017-07-17 BR BR112019000982-5A patent/BR112019000982A2/pt active Search and Examination
- 2017-07-17 US US15/651,385 patent/US10314821B2/en active Active
- 2017-07-17 AU AU2017299506A patent/AU2017299506B2/en active Active
- 2017-07-17 ES ES17752511T patent/ES2935647T3/es active Active
- 2017-07-17 CN CN201780057364.5A patent/CN109952296A/zh active Pending
- 2017-07-17 JP JP2019502219A patent/JP2019521159A/ja active Pending
- 2017-07-17 EP EP17752511.0A patent/EP3484872B1/en active Active
- 2017-07-17 WO PCT/US2017/042310 patent/WO2018017444A1/en unknown
- 2017-07-19 UY UY0001037338A patent/UY37338A/es unknown
-
2019
- 2019-01-17 MX MX2021006739A patent/MX2021006739A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| UY37338A (es) | 2018-01-31 |
| WO2018017444A1 (en) | 2018-01-25 |
| BR112019000982A2 (pt) | 2019-05-14 |
| JP2019521159A (ja) | 2019-07-25 |
| MA45685A (fr) | 2019-05-22 |
| MX2019000749A (es) | 2019-08-29 |
| TW201808941A (zh) | 2018-03-16 |
| EA201990320A1 (ru) | 2019-06-28 |
| CA3031230A1 (en) | 2018-01-25 |
| AU2017299506B2 (en) | 2021-08-05 |
| ES2935647T3 (es) | 2023-03-08 |
| US10314821B2 (en) | 2019-06-11 |
| EP3484872A1 (en) | 2019-05-22 |
| TWI752980B (zh) | 2022-01-21 |
| CN109952296A (zh) | 2019-06-28 |
| KR20190026910A (ko) | 2019-03-13 |
| EP3484872B1 (en) | 2022-11-30 |
| US20180133197A1 (en) | 2018-05-17 |
| AU2017299506A1 (en) | 2019-02-07 |
| MX2021006739A (es) | 2021-07-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12016500055B1 (en) | N,6-bis(aryl or heteroaryl)-1,3,5-triazine-2,4-diamine compounds as idh2 mutants inhibitors for the treatment of cancer | |
| CL2017001617A1 (es) | Formas sólidas de un inhibidor ask1 referencia cruzada a aplicaciones relacionadas | |
| UY37608A (es) | Derivados de pirrolo[1,2-b]piridazina | |
| MX2021014531A (es) | Compuestos de aminopurina sustituida, composiciones del mismo, y metodos de tratamiento con los mismos. | |
| AR105238A1 (es) | Compuestos de benzoxacepina oxazolidinona y métodos de uso | |
| RS54492B1 (en) | KINASE INHIBITOR REGULATING THE SIGNAL PATH OF APOPTOSIS | |
| GEP20186933B (en) | Substituted dihydroisoquinoline compounds | |
| CU20170057A7 (es) | Derivados de feniltriazol sustituido con hidroxialquilo | |
| GEP20207111B (en) | Heteroaryl compounds for kinase inhibition | |
| EA201590920A1 (ru) | Гетероарилзамещённые пиридильные соединения, применимые в качестве модуляторов киназ | |
| EA201491456A1 (ru) | Соединения-ингибиторы raf | |
| MX2017015257A (es) | Cristal de (6s, 9as)-n-bencil-8-({6-[3-(4-etilpiperazin-1-il)azeti din-1-il]piridin-2-il}metil)-6-(2-(fluoruro-4-hidroxibencil)-4,7- dioxo-2-prop-2-en-1-il)hexahidro-2h-pirazino[2,1-c] [1,2,4]triazon-1-(6h)-carboxamida. | |
| CL2019003057A1 (es) | Compuestos antitumorales. | |
| EA201591915A1 (ru) | Соединения феноксиэтил дигидро-1h-изохинолина | |
| AR103444A1 (es) | Forma cristalina de un derivado de bencimidazol y un método de preparación de los mismos | |
| EA201691999A1 (ru) | Новые сульфониламинобензамидные соединения | |
| MX2022005024A (es) | Profarmacos de fosforo de estimuladores de guanilato ciclasa soluble (sgc). | |
| PH12015502122A1 (en) | Sovaprevir polymorphs and methods of manufacturing thereof | |
| EA201892449A1 (ru) | Конденсированные гетероциклические соединения | |
| AR109079A1 (es) | Formas cristalinas de 4-ciano-n-(2-(4,4-dimetilciclohex-1-en-1-il)-6-(2,2,6,6-tetrametiltetrahidro-2h-piran-4-il)piridin-3-il)1h-imidazol-2-carboxamida | |
| MX2016001663A (es) | Combinaciones ternarias de herbicidas. | |
| BR112018012095A2 (pt) | formas sólidas de compostos substituidos de 5,6-di-hidro-6-fenilbenzo[f]isoquinolin-2-amina | |
| AR107441A1 (es) | Forma cristalina de cobicistat | |
| EA033106B1 (ru) | Производное пуринил-n-гидроксипиримидинформамида, способы его получения и его применения | |
| TN2017000065A1 (en) | A tetrahydropyrrolo[3,4-d][1,3]thiazine-derivative as bace inhibitor |